Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer

M. Bertrand, P. Multhauf, C. Presant, D. Rappaport, D. W. Blayney, B. I. Carr, G. Cecchi, J. H. Doroshow, E. Emont, D. Goldberg

Research output: Contribution to journalArticle

Abstract

Twenty-two patients with advanced non-small cell lung cancer (NSCLC), previously unexposed to chemotherapy, were treated with a combination of vincristine (1.4 mg/m2 iv) on Day 1, cisplatin (40 mg/m2 iv) on Days 1-3 and etoposide (100 mg/m2 iv) on Days 1-3 (or 80 mg/m2 iv on Days 1-3 for patients previously treated with radiation. This trial supports the conclusion of the European Organization for Research on Treatment of Cancer that this type of triple combination chemotherapy is not recommended for the treatment of NSCLC.

Original languageEnglish
Pages (from-to)1335-1336
Number of pages2
JournalCancer Treatment Reports
Volume69
Issue number11
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Bertrand, M., Multhauf, P., Presant, C., Rappaport, D., Blayney, D. W., Carr, B. I., Cecchi, G., Doroshow, J. H., Emont, E., & Goldberg, D. (1985). Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer. Cancer Treatment Reports, 69(11), 1335-1336.